DE1064001T1 - Verfahren und zusammensetzungen zur behandlung und prophylaxe von mucositis - Google Patents

Verfahren und zusammensetzungen zur behandlung und prophylaxe von mucositis

Info

Publication number
DE1064001T1
DE1064001T1 DE1064001T DE99912467T DE1064001T1 DE 1064001 T1 DE1064001 T1 DE 1064001T1 DE 1064001 T DE1064001 T DE 1064001T DE 99912467 T DE99912467 T DE 99912467T DE 1064001 T1 DE1064001 T1 DE 1064001T1
Authority
DE
Germany
Prior art keywords
mucositis
prophylaxis
compositions
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1064001T
Other languages
English (en)
Inventor
T Sonis
Edward G Fey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mucosal Therapeutics LLC
Original Assignee
Mucosal Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosal Therapeutics LLC filed Critical Mucosal Therapeutics LLC
Publication of DE1064001T1 publication Critical patent/DE1064001T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE1064001T 1998-03-13 1999-03-12 Verfahren und zusammensetzungen zur behandlung und prophylaxe von mucositis Pending DE1064001T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7797798P 1998-03-13 1998-03-13
US6501298A 1998-04-23 1998-04-23
US09/265,299 US6458777B1 (en) 1998-03-13 1999-03-09 Methods and compositions for treating and preventing mucositis
PCT/US1999/005437 WO1999045910A2 (en) 1998-03-13 1999-03-12 Methods and compositions for treating and preventing mucositis

Publications (1)

Publication Number Publication Date
DE1064001T1 true DE1064001T1 (de) 2001-12-20

Family

ID=27370718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1064001T Pending DE1064001T1 (de) 1998-03-13 1999-03-12 Verfahren und zusammensetzungen zur behandlung und prophylaxe von mucositis

Country Status (12)

Country Link
US (3) US6458777B1 (de)
EP (1) EP1064001A2 (de)
JP (2) JP2002506023A (de)
AU (1) AU753288B2 (de)
BR (1) BR9908857A (de)
CA (1) CA2323863C (de)
DE (1) DE1064001T1 (de)
GR (1) GR20010300060T1 (de)
IL (1) IL138430A0 (de)
NZ (1) NZ506931A (de)
PL (1) PL343442A1 (de)
WO (1) WO1999045910A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987552A3 (de) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulphonylharnstoff-Bindungsproteine
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6946118B1 (en) 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
WO2001019362A2 (en) * 1999-09-14 2001-03-22 Orapharma, Inc. Formulations for treating or preventing mucositis
AU778498B2 (en) * 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001066108A1 (en) * 2000-03-07 2001-09-13 Mucosal Therapeutics Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1236466B1 (de) * 2001-02-28 2011-09-21 Axiomedic Ltd. Feste selbst-haftende Zusammensetzungen zur topischen Behandlung von Störungen der Mundschleimhaut
US8980334B2 (en) * 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
US6841578B2 (en) 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
US20030059378A1 (en) * 2001-09-06 2003-03-27 Libin Barry M. Method of preventing mucositis
US20040029843A1 (en) * 2002-06-20 2004-02-12 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
EP1622577A4 (de) * 2003-04-17 2007-09-26 Univ Leland Stanford Junior Prävention von neurogenese-defiziten mit entzündungshemmenden mitteln
GB0326393D0 (en) 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2006069038A1 (en) * 2004-12-20 2006-06-29 Ariad Gene Therapeutics, Inc. Therapeutic materials and methods
PT1704860E (pt) * 2005-03-24 2010-11-16 Rottapharm Spa Derivados de benzamidina para o tratamento e prevenção da mucosite
US8568333B2 (en) * 2006-05-01 2013-10-29 Devicor Medical Products, Inc. Grid and rotatable cube guide localization fixture for biopsy device
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
US20080161248A1 (en) * 2006-12-28 2008-07-03 Wendye Robbins Methods and Compositions for Therapeutic Treatment
EP2182957A4 (de) * 2007-07-31 2012-07-18 Limerick Biopharma Inc Phosphorylierte pyronanaloge und entsprechende verfahren
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
EP2725035A1 (de) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
EP2928476B1 (de) 2012-12-07 2018-02-14 GlycoMimetics, Inc. Verbindungen, zusammensetzungen und verfahren mit e-selectin-antagonisten zur mobilisierung blutbildender zellen
CN105683208A (zh) * 2013-09-30 2016-06-15 糖模拟物有限公司 治疗和/或预防粘膜炎的方法和组合物
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
HUE045542T2 (hu) 2014-12-03 2019-12-30 Glycomimetics Inc E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai
WO2016128975A1 (en) * 2015-02-09 2016-08-18 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
AU2017341065B2 (en) 2016-10-07 2023-04-06 Glycomimetics, Inc. Highly potent multimeric E-selectin antagonists
EP3596096A1 (de) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7455064B2 (ja) 2018-03-05 2024-03-25 グリコミメティクス， インコーポレイテッド 急性骨髄性白血病および関連状態を処置する方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2023235391A1 (en) * 2022-05-31 2023-12-07 Sorrento Therapeutics, Inc. Method for treating inflammatory dysfunction of the oral mucosa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5190917A (en) 1986-12-24 1993-03-02 John Lezdey Treatment of psoriasis
EP0355067A1 (de) 1988-08-19 1990-02-21 Celltech Limited Arzneimittel gegen bösartige Gewebeneubildung
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5192780A (en) 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5824297A (en) 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5215965A (en) 1990-10-02 1993-06-01 John Lezdey Treatment of inflammation
AU1579092A (en) 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
WO1992015332A1 (en) 1991-03-04 1992-09-17 Warner-Lambert Company Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
US5310545A (en) 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
JPH0769851A (ja) 1993-09-03 1995-03-14 Lion Corp 口腔用組成物
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
JPH08168854A (ja) * 1994-12-16 1996-07-02 Nippon Steel Corp ストッパー制御方法
JPH08268854A (ja) 1995-03-31 1996-10-15 Sunstar Inc 口腔用組成物
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5788982A (en) 1995-06-16 1998-08-04 Nadoolman; Wolffe Method and composition for treating oral pain using capsaicin
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5707653A (en) * 1995-11-17 1998-01-13 Goldberg; Arthur H. Ulcer treating composition comprising sufalcrate and antibiotic
US5846525A (en) 1995-12-19 1998-12-08 Trega Biosciences, Inc. Protected biopolymers for oral administration and methods of using same
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds

Also Published As

Publication number Publication date
AU753288B2 (en) 2002-10-17
EP1064001A2 (de) 2001-01-03
GR20010300060T1 (en) 2001-11-30
JP2006206613A (ja) 2006-08-10
US20010011097A1 (en) 2001-08-02
CA2323863A1 (en) 1999-09-16
PL343442A1 (en) 2001-08-13
US20030036560A1 (en) 2003-02-20
NZ506931A (en) 2005-01-28
US6713463B2 (en) 2004-03-30
WO1999045910A2 (en) 1999-09-16
CA2323863C (en) 2005-09-13
BR9908857A (pt) 2000-10-31
IL138430A0 (en) 2001-10-31
US6458777B1 (en) 2002-10-01
WO1999045910A3 (en) 2000-02-10
AU3083799A (en) 1999-09-27
JP2002506023A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
DE1064001T1 (de) Verfahren und zusammensetzungen zur behandlung und prophylaxe von mucositis
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE69827664D1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE69920734D1 (de) VERFAHREN UND ZUSAMMENSETZUNGEN ZUR PRÄVENTION von TOLERANZ VON BRONCHODILATOREN
DE69916875D1 (de) Zusammensetzungen aus lanthanidhalogenid für die behandlung von wasser und verfahren
DE69222735D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kühlwasser
DE69834256D1 (de) Verfahren und zusammensetzung zur behandlung von verzögerten allergischen reaktionen und entzündungskrankheiten
ATE257385T1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
DE69839261D1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
DE69806970T2 (de) Verfahren zur behandlung von hartgeweben
DE69828620D1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung der chronologischer alterung der menschliches haut
DE69725169D1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
DE69609623T2 (de) Verfahren, zusammensetzungen und/oder gegenstände zur reinigung und entkeimung von nahrungsmitteln
DE69602847D1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
DE69905616D1 (de) Verfahren und zusammensetzung zur behandlung und vorbeugung von mycobacterium infektionen
DE69730042D1 (de) Zusammensetzung und Verfahren zur Behandlung von Fasern
DE69511393D1 (de) Polymerzusammensetzung und verfahren zur behandlung von metalloberflächen
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE69626311T2 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69803792D1 (de) Verfahren und zusammensetzungen zur behandlung von rheumatoider arthritis
ATE290316T1 (de) Verfahren und zusammensetzung zur antiparasitären behandlung der umgebung von tieren